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Background: Metals including iron, copper and zinc are essential for physiological processes yet can be toxic at
high concentrations. However the role of these metals in the progression of cancer is not well defined. Here we
study the anti-tumor activity of the metal chelator, TPEN, and define its mechanism of action.
Methods: Multiple approaches were employed, including cell viability, cell cycle analysis, multiple measurements of
apoptosis, and mitochondrial function. In addition we measured cellular metal contents and employed EPR to
record redox cycling of TPEN–metal complexes. Mouse xenografts were also performed to test the efficacy of TPEN
in vivo.
Results: We show that metal chelation using TPEN (5μM) selectively induces cell death in HCT116 colon cancer cells
without affecting the viability of non-cancerous colon or intestinal cells. Cell death was associated with increased levels of
reactive oxygen species (ROS) and was inhibited by antioxidants and by prior chelation of copper. Interestingly, HCT116
cells accumulate copper to 7-folds higher levels than normal colon cells, and the TPEN-copper complex engages in redox
cycling to generate hydroxyl radicals. Consistently, TPEN exhibits robust anti-tumor activity in vivo in colon cancer mouse
xenografts.
Conclusion: Our data show that TPEN induces cell death by chelating copper to produce TPEN-copper complexes that
engage in redox cycling to selectively eliminate colon cancer cells.
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Cancer is one of the leading causes of mortality and
represents a tremendous burden on patients and
societies. Colorectal cancers are associated with one of
the highest morbidity and mortality rates in both men
and women (Globocan 2008, IARC 2010). Although the
etiology of cancer varies greatly between different types
of neoplasms, a hallmark finding is a defect in cell
cycle regulation [1,2]. Such cell cycle disruption is
associated with genomic instability, due to mutations and
chromosomal aberrations that disrupt critical housekeeping* Correspondence: amro@aub.edu.lb; khm2002@qatar-med.cornell.edu
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unless otherwise stated.functions, including DNA repair and cell cycle checkpoints.
Because these homeostatic mechanisms are essential for
both normal and cancerous cells, treatments targeted at
selectively destroying cancer cells become challenging.
The G2-M transition marks the entry of cells into the
division phase of the cell cycle. Interestingly, metal
chelation using the acyclic amino metal chelator N,
N, N’, N’-tetrakis-[2-pyridylmethyl]-ethylenediamine (TPEN)
prevents frog oocytes from entering meiosis [3]. TPEN,
an uncharged polydentate ligand with nitrogens as
donor atoms, has remarkably high affinity for a broad
spectrum of metal ions, including copper, iron and zinc
[4]. TPEN-induced meiotic arrest is due to the lack of
activation of Cdc25C, a dual specificity phosphatase
in oocytes that represents the rate limiting step in
activating the master regulator of the G2-M transitiontd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Cdc25C is a Zn2+-binding protein and removal of Zn2+
inhibits its ability to interact with and dephosphorylate
Cdk1 [3]. TPEN treatment also results in meiosis arrest in
mouse oocytes [6].
TPEN-dependent metal chelation has noticeably
distinct effects during the mitotic cell cycle as compared
to meiosis. TPEN induces apoptosis in different cell
types, including lymphocytes and splenocytes [7,8],
epithelial cells [9], hepatocytes [10], breast cancer [11],
HT-29 colorectal cancer [12], ovarian cancer [13],
pancreatic cancer [14], and prostate cancer [15].
However the mechanisms of actions proposed for the
TPEN-dependent cell killing are quite varied: TPEN
was proposed to decrease the levels of the apoptosis
inhibitor XIAP due to Zn2+ chelation [15]. Zn2+
depletion has also been implicated in mitochondrial
injury, activation of caspases (primarily caspase 3) and
apoptosis [8,9,14]. Furthermore, TPEN treatment results
in depletion of glutathione causing increased redox stress
[10]. Collectively these findings argue that TPEN induces
cell killing through varied mechanisms, which may be
expected given the diverse roles that metals chelated by
TPEN play in physiological processes. Indeed TPEN
has been used as a selective Zn2+ chelator despite the
fact that it has a significantly higher affinity for Cu2+
(Stability constant for Zn 15.5 and for Cu 20.5) [16].
There is evidence at least in the hippocampus that
TPEN in vivo chelates Zn2+ with better efficiency as
compared to Cu2+ [17].
Metal homeostasis is important for biological function
and needs to be tightly regulated since either metal
deficiencies or metal excesses tend to be toxic. Metals
have played important roles in cancer treatment since
ancient times with the use of arsenic trioxide to treat
different cancers including leukemia in the 18th and 19th
century [18]. More recently platinum based compounds
such as cysplatin and carboplatin have become the
chemotherapeutic agents of choice for many cancers
[19]. Interestingly cancer cells are addicted to high iron
levels and accumulate the metal through transferrin-
dependent uptake [20,21]. Furthermore cancer cells
concentrate high levels of copper, which is presumed to be
important for both angiogenesis and metastasis [22].
Therefore, transition metals are likely to play important
roles in the development and growth and neoplasms.
Here we show that TPEN-mediated metal chelation
results in selective killing of HCT116 colon cancer cells
without affecting normal cells. TPEN cytotoxicity is due
to the generation of ROS as it is reversed by antioxidants.
Interestingly, HCT116 colon cancer cells accumulate
7-fold higher levels of copper compared to normal cells.
The TPEN-copper complex undergoes redox cycling
reactions. These results suggest that TPEN chelatesaccumulated copper in HCT116 cells making it available
for redox cycling leading to cell toxicity and death. We
further show that TPEN effectively inhibits colon cancer
tumor growth in human colon cancer xenografts in mice.
Therefore metal chelation provides a promising selective
approach to target colon cancer.
Methods
Cell culture
Human colorectal cancer cells, SW480, HT-29 and
LOVO were kindly provided by the American Type
Culture Collection (ATCC). Cells were cultured in
RPMI 1640 (Sigma-Aldrich, UK) with 20mM HEPES
and L-Glutamine at 37°C in a humidified atmosphere
of 5% CO2 and 95% air. Media was supplemented
with 1% Penicillin-Streptomycin (100 U/ml) and 10%
heat-inactivated FBS (Sigma-Aldrich, Germany). Unless
otherwise mentioned, cells were seeded at 1.2 ×105 cells/ml
and treated with TPEN (Sigma-Aldrich) at 50% confluence.
TPEN was prepared in DMSO and the final DMSO
concentration used on cells <0.3%.
Cell viability assays & antibodies
Human HCT116 p53+/+ colon cancer cells were cultured as
previously described [23]. Cell viability was measured using
the MTT-based Cell Titer 96 non-radioactive cell prolifera-
tion kit (Promega Corp, Madison, Wisconsin, USA). Cell
cycle analyses were performed on propidium iodide stained
cells using flow cytometry (Becton Dickinson, Research
Triangle, NC). The TUNEL assay used the In Situ Cell
Death Detection Kit according to the manufacture
instructions (Roche Diagnostics Corporation, Mannheim,
Germany). For Annexin V staining cells were incubated in
Annexin-V-Fluos labeling solution [20 μl Annexin reagent
and 20 μl PI (50 μg/ml) in 1000 μl incubation buffer pH
7.4 (10 mM Hepes/NaOH, 140 mM NaCl, 5 mM CaCl2),
then analyzed by flow cytometry. Caspase 3, 8 and 9
activities were assessed using Colorimetric Assay kits
according to manufacturer insutructions (R & D
Systems-BF4100). Primary antibody used for Western blots:
XIAP #2042S; Caspase 3 #9665S; Caspase 9 #9502S;
Bax #2772; PARP #9542S, from Cell Signaling. Cytochrome
C sc-13560 from Santa-Cruz and GAPDH #5476 from
Abnova.
DCFH assay
Cells were treated with TPEN for 10, 20, 30 and 45 min.
In experiments which involved addition of the anti-
oxidant N-acetyl-L-cysteine (NAC), cells were treated
with 5 mM NAC for 2 h before TPEN after which 10 μM
of the CM-H2DCFDA dye was added for 20 min. Cells
were washed, harvested by centrifugation and the pellet
washed and re-suspended in 500 μl PBS followed by flow
cytometery.
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Cells were washed, pelleted and incubated in 500 μl of
rhodamine buffer [5 μm rhodamine 123, 130 mM NaCl,
5 mM KCl, 1 mM Na2HPO4, 1 mM CaCl2, 1 mM CaCl2,
1 mM MgCl2, and 25 mM Hepes (pH7.4)] for 30 min at
37°C, then analyzed by flow cytometry.
Atomic absorption
106 HCT116 and NCM460 cells were collected in 8 ml
HNO3 65% + 2 ml H2O2 30% and digested in a closed
vessel microwave (Milestone ETHOS PLUS with
HPR-1000/10S high pressure rotor). Cell lysates were
measured for ion concentration against standard solutions
prepared for Copper, Zinc and Iron in deionized water in
an atomic absorption spectrophotometer (Furnace).
UV/VIS and EPR spectroscopy
EPR spin-trapping experiments were carried out with a
JEOL-RE1X spectrometer (Kyoto, Japan). Spectrometer
settings were as follows: field center, 335.094 mT; micro-
wave power, 10 mW; sweep time, 2.0 min; time constant,
0.3 s; and modulation width, 0.2 mT). UV/VIS spectra were
recorded with Helios Alpha spectrophotometer (Thermo
Fisher Scientific, Inc.; Pittsburgh, PA). All measurements
were performed at room temperature.
Mouse xenografts
NOD/SCID female mice, (6–8 weeks, ~20 g) (Charles
River Laboratories, France) were divided into two groups
of 8 mice each and maintained in Maxi-miser hepafiltered
facility. 2-3×106 HCT-116 tumor cells in 100 μl of 0.9%
NaCl were inoculated subcutaneously in the flank. An
average age (6–8 weeks) and body weight of mice (18-22 g)
were used for the experiments. Prior to manipulations,
mice were anaesthetized with isoflurane (Forane®, Abbott)
by inhalation. On day 7 post inoculation mice received i.p.
injections of either saline (control) or 20 mg/kg TPEN
every other day for 28 days. Tumor measurements were
performed 3 times per week using a sterile Vernier caliper.
Tumor volume was calculated by the formula: Volume = π/
6 (length × width × height). A 5-10% loss of body weight
was detected in mice receiving TPEN treatment in com-
parison to the control but they otherwise looked healthy
and tolerated the drug treatment well. The use of labora-
tory animals was in accordance with the guidelines of the
Institutional Animal Care and Use Committee (IACUC).
The IACUC committee at the American University
of Beirut where the animal studies were conducted
reviewed and approved the studies described.
Immunohistochemical analysis of xenografts
Tissue sections (4 μm) were stained with and anti-Ki-67
antibody (Santa-Cruz, US), for 60 min followed by
secondary and tertiary antibodies and incubated withthe chromogen (Zymed, US) before counterstaining
with Hematoxylin. To assess the extent of total cell death,
tissue sections were stained by using the terminal deoxyri-
bonucleotidyl transferase-mediated dUTP-nick-end labeling
(TUNEL) assay, according to manufacturer’s instructions
(in situ cell death detection kit, fluorescein; Roche) and
counterstained with PI. Slides were analyzed under
LSCM fluorescent confocal microscope (LSM 410,
Zeiss, Germany).
Statistical analyses
Data are expressed as the mean ± standard deviation,
and statistical significance between different groups was
determined using a two-tailed Student’s t-test. Statistical
significance was defined as a *p < 0.05 and **p < 0.01.
Results
TPEN selectively kills HCT116 human colon cancer cells
Treatment of HCT116 colon cancer cells with 5 μM
TPEN for 24 h results in a noticeable decrease in cell
density (Figure 1A). In contrast, non-cancerous colon
(NCM460) or intestinal (FHS74Int) cell lines (see methods
for cell lines description) were resistant to TPEN at these
concentrations (Figure 1A). A dose response of TPEN
toxicity in the two non-cancerous (NCM460 and FHS74Int)
and in four independent human colorectal cancer cell
lines (HCT116, SW 480, HT-29, and LOVO), consistently
revealed a significantly higher sensitivity of the cancerous
cells as compared to their non-cancerous counterpart.
The IC50 for the non-cancerous cells was 8.3 μM and
13μM for the NCM460 and FHS74Int respectively. In
contrast the IC50 for the cancerous cells were 2.7; 4.0; 4.3
and 4.5 μM for the HCT116; SW480; HT-29 and LOVO
cells respectively. Importantly, selective killing of
cancerous cells (15.3 ± 0.4%; 25.07 + 6%; 10.82 + 1.18%;
33.35+ 5.22% survival for HCT, SW, LoVo, HT respectively)
could be achieved at 5 μM TPEN for 24 h, concentrations
at which 96.9 ± 7.52% and 95.3 ± 1.7% of the NCM460 and
FHS74Int cell lines remained viable (Figure 1B). Flow
cytometry analysis in HCT116 cells showed that TPEN
toxicity is time-dependent as indicated by the gradual
enrichment of the pre-G1 percentage in the cell popu-
lation (Figure 1C). No obvious cell cycle arrest was
associated with the TPEN treatment (Figure 1C), indicating
that the primary effect of TPEN on HCT116 cells is
to induce cell death.
TPEN induces apoptosis in HCT116 cells
The observed increases in the PreG1 population are
associated with higher levels of apoptosis, as indicated by
TUNEL and Annexin V assays in TPEN treated cells in a
dose-dependent fashion (Figure 1D). An early hallmark of
most apoptotic cell death is increased mitochondrial
membrane permeability. TPEN induced permeabilization
Figure 1 TPEN selectively kills colon cancer cells. A) Morphology of HCT116, NCM460, and FHS74Int cell lines with and without treatment
with 5 μM TPEN for 24 h. B)Cell viability measured using the MTT assay as a function of TPEN concentrations in NCM 460, FHS74Int, HCT 116,
SW480, LoVo and HT-29 cells (mean ± SD, n = 3). C) The mean percentage of cells in each cell cycle phase after DNA staining with PI and flow cyotmetry.
D) TUNEL and Annexin assays in control cells and cells treated with TPEN 3 and 5 μM (mean ± SD, n = 3, ** p < 0.01, significant difference with respect to
control). E) Rhodamine assay measuring disruption of mitochondrial membrane potential after TPEN treatment at 3, 5 and 10 μM (mean ± SD, n = 3).
F) Time-dependent release of cytochrome c from mitochondria into the cytoplasm after TPEN treatment. G-I) TPEN alters the expression of several
proteins involved in the apoptotic pathway in a time dependent manner. PARP, caspase-9 and caspase-3 were cleaved in response to TPEN. Bax levels
were increased at 12 and 24 h of treatment.
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in mitochondrial membrane potential (ΔΨm) (Figure 1E).
Interestingly, this effect may be associated with TPEN’s
ability to “extract” essential metals, particularly iron
and copper from mitochondrial electron carriers, thus
facilitating the loss of membrane potential and the
deviation of electron flow to molecular oxygen O2 to
generate superoxide and H2O2. Treatment with TPEN
induced disruption of the mitochondrial membrane
potential in a dose-dependent fashion, as detected by the
reduced accumulation of the fluorescent dye rhodamine
(Figure 1E). Consistently, disruption of the mitochondrial
membrane is associated with the release of cytochromec from the mitochondria and its accumulation in the
cytosolic fraction (Figure 1F).
These results argue that TPEN induces apoptosis in
HCT116 cells through the intrinsic pathway. In agreement
with this conclusion, TPEN modulated key markers of
apoptosis resulting in cleavage of caspases 3 and 9 into their
active products (Figure 1G), cleavage of PARP, and accumu-
lation of the pro-apoptotic BAX, which is typically observed
upstream of mitochondrial dysfunction (Figure 1H). TPEN
killing of cancer cells was reported to be associated with
degradation of the X-linked inhibitor of apoptosis (XIAP)
[15,24]. Consistently, treating HCT116 cells with TPEN
results in XIAP degradation (Figure 2A, XIAP). XIAP
Figure 2 TPEN-dependent cell death is partially due to apoptosis induction. A) Cleavage of PARP, caspase-3 and degradation of XIAP in
TPEN-treated cells was reversed by the addition of z-VAD-fmk or ZnSO4. B) MTT viability assay in control (−) and TPEN-treated (+) cell in the
presence of either z-VAD-fmk to inhibit caspases or ZnSO4 (mean ± SD, n = 3). C) Annexin and TUNEL assays under similar condition as in panel A)
(mean ± SD, n = 3). *p < 0.05 and ** p < 0.01, significant difference with respect to TPEN.
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that it is dependent on TPEN’s metal chelation properties
(Figure 2A). However, inhibition of caspases with the pan-
caspase inhibitor z-VAD was ineffective in blocking XIAP
degradation (Figure 2C), arguing that TPEN-dependent
XIAP degradation occurs upstream of caspase activation.
These data show that TPEN induces apoptosis with all the
associated molecular hallmarks.
The ability of TPEN to induce death of HCT116 colon
cancer cells was dependent on its metal chelation
properties, as it was reversed when TPEN was added
in the presence of ZnSO4 (Figure 2B, Zinc). TPEN is a
metal chelator with high affinity for zinc, copper and iron.
Addition of exogenous Zn2+ is expected to associate with
and saturate TPEN, preventing it from chelating other
metals in the cell. ZnSO4 addition effectively abrogated
the toxic effects of TPEN as indicated by the cell viability
assay (Figure 2B, Zinc), TUNEL and annexin staining
(Figure 2C, Zinc) and PARP, caspase 3 and XIAP cleavage
(Figure 2A, Zinc). In contrast, inhibition of caspases
using the pan-caspase inhibitor z-VAD-fmk resulted
in significant, yet only partial reversal of TPEN toxicity
(Figure 2B and 2C). z-VAD treatment effectively blocked
caspase 3 and PARP cleavage (Figure 2A), this however
was not sufficient to fully reverse TPEN-dependent cell
killing (Figure 2B and 2C, z-VAD). These results suggest
that the toxic effects of TPEN are mediated only partially
through the induction of apoptosis, and potentially invoke
other death pathways such as necrosis and autophagy.
TPEN toxicity is associated with ROS generation
To investigate mechanisms involved in TPEN-dependent
cell killing, we tested the involvement of reactive oxygen
species (ROS) production using the DCFDA assay, since
TPEN has been previously implicated in ROS production
[25]. TPEN treatment caused a significant increase in
intracellular ROS as early as 10 min after treatment, which
gradually decreased over the next 30 min (Figure 3A).This ROS increase in HCT116 was significantly higher
than that observed following the addition of 250 μM of
H2O2 (Figure 3A). In contrast, TPEN-induced ROS
production in the NCM460 normal colon cells was
significantly smaller (Figure 3A), and decayed back to
baseline with a faster time course than in HCT116 cells
(Figure 3B). Similar to the data obtained in HCT116 cells,
TPEN treatment of two other colon cancer cell lines,
SW480 and LOVO, also resulted in the production of
significantly higher levels of ROS as compared to the
normal NCM colon cells (Additional file 1: Figure S1).
These data show that TPEN induces a 6-7fold higher
ROS in colon cancer cells as compared to the normal
NCM460 cells, and that this increased ROS lasts for
tens of minutes longer in HCT116 cells (Figure 3A, 3B
and Additional file 1: Figure S1). Hence there is good
correlation between ROS induction and TPEN toxicity
in these two cell lines.
To assess whether ROS generation is involved in
mediating TPEN-induced cell death, we pretreated
HCT116 cells with antioxidants, including NAC and
vitamin E, after which cell viability and apoptosis were
assessed. As expected, the general ROS scavenger
NAC and vitamin E significantly decreased H2O2- and
TPEN-induced ROS generation (Additional file 2: Figure S2).
Antioxidants effectively prevented TPEN toxicity as
measured by cell viability (Figure 3C), TUNEL and
annexin assays (Figure 3D), and reversed caspase 3 and 9
activation (Additional file 3: Figure S3). This argues that
TPEN-mediated cell killing requires ROS production.
Furthermore, the protective effects of antioxidants are
also compatible with the idea of transition metal catalyzed
oxidative stress. However, the observed incomplete
protection by two different antioxidants – NAC and
Vit E – may indicate contribution of non-redox driven
pathways, such as Zn-dependent effects, given previous
reports that argued for a role of Zn-homeostasis in TPEN
toxicity. Nonetheless, the significant reversal of the TPEN
Figure 3 TPEN induces ROS generation in HCT116 cancer cells. A) Time course of TPEN-induced ROS generation in HCT116 and NCM460 cells.
Control (Con) represents cells that have been treated with carrier DMSO. ROS generated in response to 250 μM H2O2 is also shown (mean ± SD, n = 3).
B) Same data as in panel A) normalized to maximum levels of ROS induced in either the HCT116 or the NCM460 cells. Time zero represents carrier alone
treatment and was set at zero. C) Cell viability in cells treated with TPEN in the presence or absence of the antioxidants NAC or vitamin E (mean ± SD,
n = 3). D) Apoptosis measured using the TUNEL and Annexin assays in cells treated with TPEN in the presence and absence of NAC (mean ± SD, n = 3).
** p < 0.01, significant difference with respect to TPEN in C, and D, and with respect to control in A.
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for an essential role for ROS production in TPEN toxicity.
TPEN-metal complex are redox active
We were then interested in defining the mechanism
by which TPEN induces ROS generation and cell killing. In
the presence of ascorbic acid, TPEN has been shown to
mobilize iron from ferritin, presumably via formation
of a [TPEN-Fe(II)] complex. This reaction may have
toxicological consequences, as [TPEN-Fe(II)] can participate
in Fenton-like reactions with concomitant generation of
hydroxyl radical and/or high-valent iron (IV)-oxo species. In
addition, TPEN was suggested to deplete intracellular
copper in several cell types [11,26,27]. Hence, we carried
out experiments to verify whether ascorbic acid can reduce
[TPEN-Fe(III)] to [TPEN-Fe(II)], and [TPEN-Cu(II)] to
[TPEN-Cu(I)]. This is important in the context of the ROS
observed in response to TPEN treatment because the
reduced forms of these complexes may have the potential
to generate hydroxyl radical in the presence of H2O2.
Ascorbic acid reduces [TPEN-Fe(III)] at a relatively
low rate (Figure 4A, closed circles), thus setting the stage
for induction of a futile redox cycle whereby [TPEN-Fe(II)]
autoxidizes to [TPEN-Fe(III)] with concomitant generation
of superoxide anion radical. Incubation of ascorbic acidwith [TPEN-Cu(II)], however, did not result in
changes in the electronic spectrum of the complex
(Figure 4B). This suggests that either ascorbate does not
possess the required potential to reduce [TPEN-Cu(II)] to
[TPEN-Cu(I)], or the latter rapidly autoxidized with
generation of superoxide anion radical. To verify the
latter hypothesis, we assessed the ability of [TPEN-Cu
(II)] to generate hydroxyl radical in a reaction system
consisting of H2O2, ascorbic acid, dimethylsulfoxide
(CH3SOCH3; DMSO) and N-tert-butyl-alha-phenylnitrone
(PBN) as a spin trapping agent. In the complete reaction
system, the initial Electron Paramagnetic Resonance.
(EPR) doublet of the semidehydroascorbyl radical
(ascorbate + radicals→ semidehydroascorbyl radical) was
gradually substituted by the characteristic 6-line EPR
spectrum of PBN/.CH3 (Figure 4C; CH3SOCH3 +HO
.→ .
CH3 + CH3S (O) OH;
.CH3 + PBN→ PBN/
.CH3
. ). The for-
mation of PBN/.CH3 was inhibited by depletion of ascorbic
acid, as assessed by the disappearance of the semidehy-
droascorbyl radical. No PBN/.CH3 formation was observed
if either H2O2 or ascorbic acid was omitted from the reac-
tion system. Under these experimental conditions, the rate
of PBN/.CH3 formation by [TPEN-Fe
(III)] was 4 times
slower than that observed with [TPEN-Cu (II)] (Figure 4D).
The results obtained indicate that both [TPEN-Fe(II)] and
Figure 4 TPEN-Cu complex is redox active. A) Reduction of [TPEN-Fe (III)] and [TPEN-Cu (II)] by ascorbic acid. Reactions were carried out at 25°C
in 0.1 M phosphate buffer (pH 7.4). TPEN, ferric nitrate, copper sulfate and ascorbic acid were used at concentrations of 0.2, 0.1, 0.1 and 5 mM,
respectively. Complexes of TPEN with Cu (II) and Fe (III) were prepared via incubation of the ligand (0.3 mM) with the corresponding metal ion
(0.03 mM) for 10 min in the reaction buffer. A) Changes in the absorbance of solutions of [TPEN-Fe(III)] in the absence (open circles) and the
presence (closed circles) of ascorbic acid. B) Electronic spectrum of TPEN (1) and [TPEN-Cu(II)] in the absence (2) and the presence (3 – 5) of
ascorbic acid. Consecutive spectra were recorded with time interval of 5 min. C-D) Fenton-like reactions of [TPEN-Cu(II)] and [TPEN-Fe(III)]. C)
[TPEN-Cu(II)], ascorbic acid, DMSO, H2O2 and PBN. D) [TPEN-Fe
(III)], ascorbic acid, DMSO, H2O2 and PBN. Reactions were carried out 25°C in 0.1 M
phosphate buffer (pH 7.4). Ascorbic acid, DMSO, H2O2 and PBN were used at concentrations of 1 mM, 300 mM and 2 mM, respectively. Consecutive EPR
spectra were recorded with time interval of 5 min. E) Concentrations of copper, zinc and iron in HCT116 and NCM460 (mean ± SD, n = 3). F) Percent
copper chelated by TPEN in HCT116, Lovo and SW480 cells. Cells were treated with 5 μM TPEN for 24 h, and prepared cell lysates were filtered through
10 Kd cut off filtered to remove TPEN and TPEN-copper complexes. Copper was measured by atomic absorption in both the filtrate (TPEN Bound) and the
lysates (Protein Bound) and percentages calculated accordingly (mean ± SD, n = 3).
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biological systems ([TPEN-Me(n+)] + H2O2→ [TPEN-
Me(n+1)] + HO. + HO−). These observations extend
the reaction mechanism of the breakdown of H2O2 by
([TPEN-Fe(n+)], which includes the formation of high-
valent oxo-species that can activate C-H bonds and epoxi-
date > C =C < bonds [28-30]. Hence the TPEN-Fe and
TPEN-Cu complex engage in redox cycling resulting in the
generation of ROS. As such chelation of cellular copper
and/or iron by TPEN has the potential to produce ROS
leading to cellular toxicity.
Colon cancer cells accumulate higher levels of copper
and zinc
Given the potential of TPEN-Cu (II) and TPEN-Fe(II) to
redox-cycle in the presence of H2O2 and a reductant
(eg, ascorbate) to yield hydroxyl radicals, the abilityof these TPEN-metal complexes to produce cellular
damage is likely to be proportional to the amount of
chelatable metals in cells. Tumor tissues from multiple
cancers have been reported to have elevated copper
content [22]. This is also the case for HCT116 cells
as shown by atomic absorption spectroscopy studies,
where both copper (enriched ~7-folds) and zinc
(enriched ~5.5-folds) accumulate to significantly higher
levels as compared to NCM460 (Figure 4E). In contrast,
iron content was similar between the two cell types
(Figure 4E). Similar accumulation of copper and zinc
but not iron were observed in two additional colon
cancer cell lines, LoVo and SW480, where the measured
levels for Cu were 120.25 and 99.56 μg/L; Zn 20.34 and
15.26 μg/L; Fe 44.24 and 46.25 μg/L in LoVo and SW480
cells respectively. Given that zinc is not redox active and
that the levels of iron are similar in both cell types, the
Fatfat et al. BMC Cancer 2014, 14:527 Page 8 of 12
http://www.biomedcentral.com/1471-2407/14/527mechanisms of action of TPEN is likely to involve forma-
tion of a TPEN-Cu complex that engages in redox cycling
to generate ROS and cause cellular damage. Interestingly
the fold enrichment of copper in HCT116 cells (Figure 4E)
mirrors the fold increase in redox-cycling activity revealed
by DCFH oxidation measured in these cells as compared
to NCM460 following TPEN treatment (Figure 3A).
Cellular copper is required for TPEN toxicity
The above data support a model where TPEN induces
selective death of cancer cells through its ability to chelate
copper away from cellular proteins, resulting in the forma-
tion of a TPEN-copper complex able to engage in redox
cycling thus generating ROS and inducing cell death.
Interestingly, the TPEN-Cu complex is predicted to be
impermeant to the cell membrane, given the positive
charges contributed by the copper ion, thus trapping the
complex intracellularly and increasing the levels of ROS
produced. This model makes two testable predictions.
First, it predicts that TPEN is capable of stripping a signifi-
cant proportion of copper away from cellular proteins. To
determine whether this is the case, we measured the
fraction of total cellular copper that is chelatable by TPEN
under our experimental conditions. As shown in Figure 4F,
~50% of the total cellular copper can be chelated by TPEN
following incubation with 5μM TPEN for 24 hrs.
The second prediction from the proposed model is
that cellular copper is essential for TPEN toxicity.
Indeed if TPEN induces cell death through redox cycling
after the formation of a TPEN-Cu complex, then reducing
the enriched total cellular copper in cancerous HCT116
cells would be expected to reduce TPEN toxicity. To test
whether this is the case we incubated HCT116 with the
membrane permeant copper specific chelator neocuproine
[31]. We chose neocuproine because of its specificity for
copper and because the neocuproine-Cu complex in
unlikely to be redox active [32]. Therefore, preincubation
of HCT116 cells with neocuproine is expected to chelate
cellular copper thus preventing TPEN from binding it. In
the absence of the formation of TPEN-Cu complexes
TPEN treatment should not produce ROS. Neocuproine
by itself mildly reduces cellular viability (Figure 5A, Neo),
probably due to the requirement for copper for normal
cellular homeostasis. Importantly, incubating cells with
neocuproine does not generate ROS (Figure 5B, Neo),
showing that indeed the Neo-Cu complex is not redox
active. However, pre-incubating HCT116 cells with
neocuproine significantly reverses the toxic effect of TPEN
(Figure 5A, Neo + TPEN), and this reduction in toxicity is
coupled to a significant reduction in the levels of ROS
generated (Figure 5B, Neo + TPEN5).
To test whether neocuproine reverses TPEN toxicity
by chelating intracellular copper, we incubated cells
with a membrane impermeant copper specific chelator,bathocuproine [33]. In contrast to neocuproine, bathocu-
proine did not reverse the cellular toxicity due to TPEN
treatment (Figure 5C). Collectively these data show that
TPEN toxicity requires cellular copper. When intracellular
copper is chelated with neocuproine, a copper chelator
that is effective at chelating copper but does not allow the
TPEN-Cu complex to engage in redox reactions, TPEN
becomes ineffective at producing ROS and killing colon
cancer cells. Furthermore, as shown in Figure 2A with
zinc, copper was also effective at reversing the toxic effects
of TPEN and its ability to generate ROS in a dose
dependent fashion (Figure 5A and B), showing that TPEN
toxicity is dependent on its metal chelation properties.
Tumoristatic activity of TPEN in vivo
The ability of TPEN to selectively kill cancer cells raises
the attractive possibility that it could have anti-tumor
potential in vivo. To test whether this is the case we used
a mouse xenograft colon cancer model. HCT116 colon
cancer cells (2-3×106), were subcutaneously inoculated
into the flank of NOD/SCID mice, and showed efficient
engraftment as reflected by the development of malignant
palpable tumor mass within 7–9 days post-inoculation. To
investigate the therapeutic efficacy of TPEN, xenografted
mice were injected intraperitoneally (i.p.) at 7 days post-
inoculation with TPEN (20 mg/kg) every other day for a
22 days therapy span. Tumor size was monitored in mice
at different time points starting at day 7 post inoculation
for both groups. In the TPEN treated group tumor volume
was significantly reduced throughout the time course of
tumor development with a volume of 11.6 ± 0.37 cm3
in the control group versus 3.75 ± 0.142 cm3 in the
TPEN-treated group at day 22 (Figure 6A). In our
hands TPEN was well tolerated at 15–20 mg/kg, but
not at 30 mg/kg, consistent with previous reports [34].
Histological H & E staining of tumor sections from
untreated mice showed malignant cell infiltration and re-
tention in the tissue (Figure 6B). However, TPEN-treated
group showed a significant decrease of malignant cell
nuclei staining relative to the control mice, consistent with
the tumor growth profile (Figure 6A and B). In addition,
the expression of Ki-67, a nuclear protein proliferative
marker, was reduced in TPEN-tissue section as depicted by
immunostaining (Figure 6B). Furthermore, in vivo TPEN
treatment induced apoptosis in tumor tissue as reported by
TUNEL staining (Figure 6C). Collectively these data show
that TPEN is effective at inhibiting the growth of colon
cancer cells in vivo, arguing that metal chelation is a
promising intervention for colon cancer treatment.
Discussion
Metals such as iron, copper and zinc are essential
elements in mammalian cells and are used as cofactors or
as structural components of many enzymes. However, an
Figure 5 Cellular Cu is required for TPEN toxicity. A) Cellular
viability using the MTT assay in cells that were either untreated (CON),
incubated with CuSO4 (5 μM, Cu); neocuproine (25 μM, Neo); TPEN
(5 μM); pre-incubated with neocuproine (25 μM) for 2 h before TPEN
(5 μM) addition (Neo + TPEN); pre-incubated with CuSO4 (5 μM) before
TPEN (5 μM, Cu + TPEN5) or TPEN (15 μM, Cu + TPEN15) addition
(mean ± SD, n = 3). B) ROS induction using the DCF assay in untreated
cells (CON), cells incubated with CuSO4 (5 μM, Cu); neocuproine (25 μM,
Neo); H2O2 (250 μM); TPEN (5 μM); pre-incubated with neocuproine
(25 μM) for 2 h before TPEN (5 μM) addition (Neo + TPEN); pre-incubated
with CuSO4 (5 μM) before TPEN (5 μM, Cu + TPEN5) or TPEN (15 μM,
Cu + TPEN15) addition (mean ± SD, n = 3). C) MTT viability assay in
untreated cells (CON); cells incubated with bathocuproine ( 5 and
10 μM) or TPEN (5 μM), and in cells pre-incubated with bathocuproine
(5 or 10 μM) for 2 hours before the addition of TPEN (5μM) (mean ± SD,
n = 3, ** p < 0.01, significant difference with respect to TPEN in A and B).
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between metal accumulation, their sequestration within
cellular compartments, and their association with cellular
proteins is essential for the maintenance of cell viability
[35,36]. Transient intracellular elevations of free iron
or copper is toxic because of their redox reactivity
and participation in ROS metabolism. In particular,
low molecular mass complexes of Fe (II) and Cu (II) can
react with hydrogen peroxide to generate hydroxyl radical,
which is believed to be the most toxic form of ROS
encountered in cells.
Here we show that this detrimental effect of transition
metals can be used effectively to selectively eliminate
cancer cells. TPEN is efficient at selectively eliminating
colon cancer cells both in the dish and in vivo in mice.
The mechanism of action of TPEN depends first on
its high affinity for metals and as such its ability to
strip intracellular metals from cellular proteins. Second
colon cancer cells accumulate copper to significantly higher
levels than normal colon cells. Finally, the TPEN-copper
complex engages in redox cycling and the generation of
ROS (hydroxyl radicals). Hence, TPEN selectively elimi-
nates colon cancer cells using an elegant mechanism that
relies on the biology of the cancer through its tendency to
accumulate copper, a feature that is common to many other
cancers including breast, ovarian, stomach, colorectal and
leukemia [22]. As such the TPEN-dependent selective
killing observed in this study is likely to be applicable to
other cancers that accumulate redox active metals.
However, TPEN anti-tumor activity is likely to involve
additional mechanisms since antioxidants treatment was
not fully effective at reversing TPEN toxicity (Figure 3).
TPEN toxicity is likely to be partly due to the removal of
zinc from essential Zn-dependent proteins as previously
reported by others [7-15].
Another metal chelator that shows selective antitu-
mor activity is di-2-pyridylk-etone-4,4,-dimethyl-3-
thiosemicarbazone (Dp44mT). Dp44mT is thought to

























Figure 6 TPEN decreases the volume of colon cancer xenografts in mice. A) Graph showing a significant decrease in the volume of HCT116
colon cancer xenografts in mice injected with 20 mg/kg TPEN i.p., three times per week for 22 days. Tumor volumes were significantly smaller in
TPEN-treated mice as compared to saline injected (Con) starting at day 6 after treatment (mean ± SEM, n = 7-8, ** p < 0.01, significant difference with
respect to Con in A). B) Histological (H & E) and immunohistochemical (Ki-67 antibody) staining in tumor xenografts. C) Apoptosis staining is revealed
by using the TUNEL assay. Tissue was processed as described in “Methods.” Identical fields are shown for propidium iodide (PI) stain of all nuclei
(red fluorescence), and for fluorescein-labeled detection of TUNEL-positive nuclei (green fluorescence). Representative images were taken at 400×
magnification. Scale Bar, 50 μm.
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and redox cycling to generate ROS [37,38]. Dp44mT
toxicity is also believed to involve activation of the
lysosomal apoptotic pathway through its copper binding
capacity [20].
Interestingly, cancer cells are known to have an altered
redox status with an up-regulation of oxidative stress and
an augmentation of antioxidant capacity (reviewed in [39]).
It is also thought that a moderate increase in ROS enhances
cell survival and proliferation [40]. Therefore the observed
increase in ROS in cancer cells may promote tumorigenesis
[39]. However, the increased basal ROS in cancer cells
brings them closer to the toxicity threshold where the
intrinsic antioxidant capacity, although enhanced, is not
sufficient to contain toxic ROS levels [39]. Therefore
increased oxidative stress in cancer cells represents an
effective mechanism to eliminate cancer cells [39].
In summary, selective killing of colon cancer cells can be
achieved using TPEN, where the transition metal-chelator
complex engages in redox cycling and the generation of
hydroxyl radicals. This is an attractive potential anti-
tumor therapeutic approach because its mechanism of ac-
tion depends on the biology of cancer cells, including the
significant accumulation of copper and their endogenous
enhanced oxidative stress. Therefore, selectivity toward
elimination of cancer cells without affecting normal cells
is inherent in this approach because of different homeo-
static mechanisms in cancer versus normal cells. In that
context it would be attractive to systematically explore the
redox cycling potential of metal chelators already in the
clinic for the treatment of other diseases.
Conclusions
TPEN, a membrane permeant metal chelator, selectively
kills colon cancer cells without affecting the viability ofnormal cells. TPEN is effective at preventing tumor growth
in a xenograft model. The mechanism of action of TPEN
involves chelation of intracellular copper, making it avail-
able for redox cycling thus leading to the generation of
ROS and cell death. Because colon cancer cells accumulate
copper to 7 folds higher levels than control cells, this
endows TPEN with its selective killing ability. Therefore,
the mechanism of action of TPEN offers an attractive anti-
tumor therapeutic approach potentially for a multitude of
cancers that accumulate copper.
Additional files
Additional file 1: Figure S1. TPEN induces high ROS levels in
cancerous but not normal colon cells. Time course of TPEN-induced ROS
generation in LoVo, SW480 and NCM460 cells. Control (Ctrl) represents
cells that have been treated with DMSO carrier alone. ROS generated in
response to 250 mM H2O2 is also shown as a control (mean ± SD, n = 3).
** p < 0.01, significant difference with respect to Ctrl.
Additional file 2: Figure S2. Antioxidants prevent TPEN-induced ROS
generation in HCT116 cancer cells. Pretreatment with the antioxidants
NAC or vitamin E decreased ROS production in cells treated with TPEN.
ROS generated in response to 250mM H2O2 is also shown as a control
(mean ± SD, n = 3). **p < 0.01, significant difference with respect to TPEN.
Additional file 3: Figure S3. Effect of TPEN on caspase activity. TPEN
treatment (TPEN) significantly increased caspase-3 (A) and caspase-9 (B)
above baseline (Ctrl). Pre-treatment with the antioxidant NAC decreases
caspase-3 (A) and caspase-9 (B) activity below baseline levels at 12 h.
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